Richard D. Carvajal, MD

Articles

Dr. Richard Carvajal on Selumetinib/ Dacarbazine in Uveal Melanoma

March 10th 2016

Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses the phase III SUMIT trial, a randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma.

Community and the Care of Patients With Rare Cancers

April 6th 2015

Richard D. Carvajal, MD discusses the significance of researching, understanding, and improving outcomes for patients with rare cancers.

Dr. Carvajal on Vaccine Challenges in Cancer Therapy

April 6th 2015

Richard D. Carvajal, MD, Director, Experimental Therapeutics and Melanoma Service New York-Presbyterian Hospital/ Columbia University Medical Center, discusses the challenge of using vaccines for cancer therapy.

Dr. Carvajal on the Design of a Trial in Uveal Melanoma

September 25th 2013

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the design of a phase II study of selumetinib versus temozolomide in uveal melanoma with GNAQ/GNA11 mutations.

Dr. Richard D. Carvajal on the Investigation of Selumetinib

July 25th 2013

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the background of the investigation of selumetinib for advanced uveal melanoma.

Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma

June 1st 2013

Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.